Labs / CDMO: development & manufacturing

Chongqing Sintaho Pharmaceutical Co., Ltd.
Chongqing, China · en.sintaho.com
GMP · GLP
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Chongqing Sintaho Pharmaceutical Co., Ltd. is an API enterprise founded in 2016 in Banan District, Chongqing, China. It provides R&D, production, registration, domestic and international marketing of APIs, with business focused on high-potency/cytotoxic APIs, peptides, and XDC compounds.
Their website has a general contact form; we send your quote request through it.
What they offer
API R&D
Develops active pharmaceutical ingredients across its business segments.
API production
Manufactures APIs through its GMP supporting systems and dedicated production lines.
API registration support
Supports registration activities for APIs.
Domestic and international API marketing
Markets APIs in China and overseas markets.
CDMO services
Provides contract development and manufacturing services for global partners.
CMO services
Provides contract manufacturing services for global partners.
High-potency API development and manufacturing
Works on high-potency and cytotoxic API programs using dedicated production lines.
Peptide development and manufacturing
Develops and manufactures peptide products, including GLP-1 APIs.
XDC compound development and manufacturing
Develops and manufactures XDC compounds and related linker-payload combinations.
Structural modification
Offers structural modification as part of its C(D)MO portfolio.
Regulatory filing support
Supports DMF, CEP, and ASMF filings.
Process scaling
Scales processes from gram to hundred-kilogram batches.
Commercial supply
Provides commercial supply for API and related projects.
Full-life-cycle management
Supports post-approval change management, CPV, and responses to pharmacopoeia method revisions.
What they work on
- Modalities
- Small molecule, ADC, Peptide
- Assays and studies
- HPLC purity, single-impurity control, impurity profiling, structural characterization, immunogenicity risk assessment, genotoxic impurity (GTI) control
- Instruments and platforms
- fully closed isolator systems
- Scale and capacity
- approximately 55,000 m² of GMP-compliant manufacturing space, 1,500 kg-per-annum peptide production line for GLP-1 APIs, commercial-scale manufacturing of high-potency compounds up to 50 kg
- Type
- CRDMO
- Sites
- Chongqing, China
- Quality
- GMP (long-time GMP compliance) · US FDA on-site inspection (passed in 2024 and 2025) · Australian TGA remote GMP inspection (passed in 2022) · France ANSM on-site inspection (passed in 2017)
- Serves
- China, United States, Canada, European Union, more than 30 countries
- Founded
- 2016
Similar labs. Gannet BioChem, Porton, TRACER, Veranova
Found in a contract services directory. Listing built from en.sintaho.com. Work here? Claim this listing.